scispace - formally typeset
I

Ilana Schlam

Researcher at MedStar Washington Hospital Center

Publications -  27
Citations -  236

Ilana Schlam is an academic researcher from MedStar Washington Hospital Center. The author has contributed to research in topics: Medicine & Breast cancer. The author has an hindex of 5, co-authored 13 publications receiving 79 citations. Previous affiliations of Ilana Schlam include Jewish Hospital & Mayo Clinic.

Papers
More filters
Journal ArticleDOI

HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now.

TL;DR: A review of currently approved TKIs for HER2+breast, key clinical trials, and their use in current clinical practice can be found in this paper, where the authors present a comparison of different types of therapies.
Journal ArticleDOI

Best Practices for Spatial Profiling for Breast Cancer Research with the GeoMx® Digital Spatial Profiler.

TL;DR: The GeoMx Digital Spatial Profiler (DSPP) as mentioned in this paper enables researchers to spatially resolve and quantify proteins and RNA transcripts from tissue sections, which is compatible with both formalin-fixed paraffin-embedded and frozen tissues.
Journal ArticleDOI

Carfilzomib: A cause of drug associated thrombotic microangiopathy.

TL;DR: Two cases of biopsy proven thrombotic microangiopathy that occurred after the initiation of carfilzomib for relapsed multiple myeloma are described and TPE is suggested to be not beneficial for treating carfilZomib-induced TMA.
Journal ArticleDOI

PKM2 and other key regulators of Warburg effect positively correlate with CD147 (EMMPRIN) gene expression and predict survival in multiple myeloma.

TL;DR: PKM2 and other key regulators of Warburg effect positively correlate with CD147 (EMMPRIN) gene expression and predict survival in multiple myeloma.
Journal ArticleDOI

Overcoming Resistance to HER2-Directed Therapies in Breast Cancer

TL;DR: In this paper , the authors discuss the mechanisms of resistance to different HER2-targeted therapies, including monoclonal antibodies, small tyrosine kinase inhibitors, and antibody-drug conjugates.